1Douthwaite J A,Johnson T S,Haylor J L,et al.Effects of transforming growth factor-betal on renal extracellular matrix components and their regulating proteins[J].J Am Soc Nephrol,1999,10:2109—2119.
2Fomoni A, Striker L J, Zheng F, et al. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background [ J ]. Diabetes,2002, 51 : 499-505.
3Mizuno S, Matsumoto K, Kurosawa T, et al. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice [ J ]. Kidney Int,.2000, 57: 937-948.
4Hulboy D L, Rudolph L A, Matrisian L M. Matrix metalloproteinases as mediators of reproductive function [ J ]. Mol Hum Reprod, 1997, 3: 27-45.
5Wojtowicz-Praga S M, Dickson R B, Hawkins M J. Matrix metalloproteinase inhibitors [ J ]. Invest New Drugs, 1997,15 : 61-75.
6Park H I, Ni J, Gerkema F E, et al. Identification and characterization of human endometase (Matrix metalloproteinase-26 ) from endometrial tumor [J] . J Biol Chem,2000, 275 : 20540-20544.
7Marchenko G N, Strongin A Y. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors [J]. Gene, 2001,265 : 87-93.
9Gomez D E. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions[J]. Eur J Cell Biol, 1997, 74:111 ~ 122.
10Chen S, Hong S W, lglesias-de la Cruz M C, et al. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy[J]. Renal Fail, 2001,23 : 471-481.
